Northwest Biotherapeutics (OTCMKTS:NWBO) Issues Quarterly Earnings Results

Key Points

• Northwest Biotherapeutics reported earnings of ($0.01) per share for the recent quarter, indicating continued financial challenges for the company.
• The stock price of NWBO increased by 0.8%, trading at $0.24, with a significant volume of 861,498 shares exchanged.
• Northwest Biotherapeutics specializes in developing personalized immune therapies for cancer, leveraging a technology platform called DCVax to stimulate the patient's immune system.

Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $0.13 million for the quarter.

Northwest Biotherapeutics Stock Down 5.2%

Shares of OTCMKTS:NWBO traded down $0.0133 during trading on Tuesday, reaching $0.2402. 2,020,071 shares of the company traded hands, compared to its average volume of 3,286,098. The firm has a fifty day simple moving average of $0.25 and a 200 day simple moving average of $0.26. Northwest Biotherapeutics has a 1-year low of $0.1685 and a 1-year high of $0.4788. The firm has a market cap of $356.06 million, a P/E ratio of -4.00 and a beta of -1.14.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.